S-3ASR EX-FILING FEES 0001553643 N/A N/A 0001553643 1 2026-05-12 2026-05-12 0001553643 2 2026-05-12 2026-05-12 0001553643 3 2026-05-12 2026-05-12 0001553643 4 2026-05-12 2026-05-12 0001553643 5 2026-05-12 2026-05-12 0001553643 6 2026-05-12 2026-05-12 0001553643 7 2026-05-12 2026-05-12 0001553643 8 2026-05-12 2026-05-12 0001553643 2026-05-12 2026-05-12 iso4217:USD xbrli:pure xbrli:shares

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

S-3

Relmada Therapeutics, Inc.

Table 1: Newly Registered and Carry Forward Securities

                                                             
Line Item Type   Security Type   Security Class Title   Notes   Fee Calculation
or Carry Forward Rule		   Amount Registered   Proposed Maximum Offering
Price Per Unit		   Maximum Aggregate Offering Price   Fee Rate     Amount of Registration Fee   Carry Forward Form Type   Carry Forward File Number   Carry Forward Initial Effective Date   Filing Fee Previously Paid in Connection with
Unsold Securities
to be
Carried Forward
                                                             
Newly Registered Securities
Fees to be Paid   Equity   Common Stock, $0.001 par value per share    (1)   457(r)       $     $     0.0001381   $                 $  
Fees to be Paid   Equity   Preferred Stock, $0.001 par value per share    (2)   457(r)                   0.0001381                        
Fees to be Paid   Equity   Depositary Shares    (3)   457(r)                   0.0001381                        
Fees to be Paid   Other   Subscription Rights    (4)   457(r)                   0.0001381                        
Fees to be Paid   Other   Warrants    (5)   457(r)                   0.0001381                        
Fees to be Paid   Other   Purchase Contracts    (6)   457(r)                   0.0001381                        
Fees to be Paid   Other   Units    (7)   457(r)                   0.0001381                        
Carry Forward Securities
Carry Forward Securities   Equity   Common Stock, $0.001 par value per share    (8)   415(a)(6)       $     $ 50,000,000.00       $     S-3   333-281877   09/12/2024   $ 7,380.00
                                                             
Total Offering Amounts:   $ 50,000,000.00         0.00                  
Total Fees Previously Paid:               0.00                  
Total Fee Offsets:               0.00                  
Net Fee Due:             $ 0.00                  

__________________________________________
Offering Note(s)

(1) Represents securities that may be offered and sold from time to time in one or more offerings by Relmada Therapeutics, Inc. (the “Registrant”)

An indeterminate aggregate initial offering price or number of securities of each identified class is being registered as may from time to time be issued at indeterminate prices and as may be issuable upon conversion, redemption, exchange, exercise or settlement of any securities registered hereunder, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder.

The proposed maximum aggregate offering price per class of security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, the registrant is deferring payment of all registration fees.
(2) Represents securities that may be offered and sold from time to time in one or more offerings by Relmada Therapeutics, Inc. (the “Registrant”)

An indeterminate aggregate initial offering price or number of securities of each identified class is being registered as may from time to time be issued at indeterminate prices and as may be issuable upon conversion, redemption, exchange, exercise or settlement of any securities registered hereunder, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder.

The proposed maximum aggregate offering price per class of security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, the registrant is deferring payment of all registration fees.
(3) Represents securities that may be offered and sold from time to time in one or more offerings by Relmada Therapeutics, Inc. (the “Registrant”)

An indeterminate aggregate initial offering price or number of securities of each identified class is being registered as may from time to time be issued at indeterminate prices and as may be issuable upon conversion, redemption, exchange, exercise or settlement of any securities registered hereunder, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder.

The proposed maximum aggregate offering price per class of security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, the registrant is deferring payment of all registration fees.
(4) Represents securities that may be offered and sold from time to time in one or more offerings by Relmada Therapeutics, Inc. (the “Registrant”)

An indeterminate aggregate initial offering price or number of securities of each identified class is being registered as may from time to time be issued at indeterminate prices and as may be issuable upon conversion, redemption, exchange, exercise or settlement of any securities registered hereunder, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder.

The proposed maximum aggregate offering price per class of security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, the registrant is deferring payment of all registration fees.
(5) Represents securities that may be offered and sold from time to time in one or more offerings by Relmada Therapeutics, Inc. (the “Registrant”)

An indeterminate aggregate initial offering price or number of securities of each identified class is being registered as may from time to time be issued at indeterminate prices and as may be issuable upon conversion, redemption, exchange, exercise or settlement of any securities registered hereunder, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder.

The proposed maximum aggregate offering price per class of security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, the registrant is deferring payment of all registration fees.
(6) Represents securities that may be offered and sold from time to time in one or more offerings by Relmada Therapeutics, Inc. (the “Registrant”)

An indeterminate aggregate initial offering price or number of securities of each identified class is being registered as may from time to time be issued at indeterminate prices and as may be issuable upon conversion, redemption, exchange, exercise or settlement of any securities registered hereunder, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder.

The proposed maximum aggregate offering price per class of security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, the registrant is deferring payment of all registration fees.
(7) Represents securities that may be offered and sold from time to time in one or more offerings by Relmada Therapeutics, Inc. (the “Registrant”)

An indeterminate aggregate initial offering price or number of securities of each identified class is being registered as may from time to time be issued at indeterminate prices and as may be issuable upon conversion, redemption, exchange, exercise or settlement of any securities registered hereunder, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder.

The proposed maximum aggregate offering price per class of security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, the registrant is deferring payment of all registration fees.
(8) Pursuant to Rule 415(a)(6) under the Securities Act, this registration statement includes $50,000,000 of unsold securities (the “Unsold Securities”) that had previously been registered under the Registrant’s registration statement on Form S-3 (File No. 333-281877) initially filed on August 30, 2024, and effective on September 12, 2024 (the “Prior Registration Statement”) and paid a filing fee of $36,900 for an aggregate of $250,000,000 of securities that could have been issued under the Prior Registration Statement. Pursuant to Rule 415(a)(6), the Registrant is carrying forward to this registration statement the Unsold Securities that were previously registered on the Prior Registration Statement, and the aggregate filing fees of approximately $7,380 previously paid in connection with the Unsold Securities will continue to be applied to the Unsold Securities that are being carried forward to this registration statement.